Leveraging Human Primary Cell In Vitro Assays to Advance Immune Targeted Cancer Therapeutics

Watch our webinar on primary cell assays for antibody-targeted therapeutic candidates.
Our Senior Study Manager, Dr. Gavin Meehan describes and discusses the different in vitro assays currently available for immuno-oncology drug discovery; he also provides an overview of the new assay platforms in development at Antibody Analytics.
In addition, he will explore our IndEx-2 dual inducible in vitro cell line system and how it can be used in combination with our primary cell platforms to determine thresholds of activation delving into the potential of ‘on-target/off-tumour’ effects for antibody-targeted therapeutic candidates.
What is be covered in the webinar?
- Learn about the various primary immune cell systems available for characterising immunotherapies
- Discover how inducible cell lines can help better determine safety and efficacy features in vitro
- Explore how the transition towards more complex systems such as tissue organoids can provide more translational data
About Antibody Analytics
Antibody Analytics is a leader in quality immunology research services. Providing physiologically relevant in vitro models to select and characterise biologics and novel immunotherapies. Expertise spans human primary immune cells, cell line engineering, antibody effector function packages, bioassay development and SPR to support biopharmaceutical companies to overcome substantial scientific challenges.
The webinar was originally hosted by Select Science on 28th May 2024.
#immunotherapy #index2 #immunology #cancertreatment